ALBIREO PHARMA,INC. (NASDAQ:BIOD) Files An 8-K Financial Statements and Exhibits

ALBIREO PHARMA,INC. (NASDAQ:BIOD) Files An 8-K Financial Statements and Exhibits

Story continues below

Item9.01(a) of Form 8-K. Such financial information was excluded
from the Original Form 8-K in reliance on the instructions to
such Item.

Item9.01. Financial Statements and Exhibits.

(a)Financial Statements of Businesses Acquired.

The unaudited financial statements of Albireo as of September30,
2016 and for the three and nine months ended September30, 2016
and 2015 are filed herewith as Exhibit 99.4.

(d)Exhibits

Exhibit No.

DescriptionofExhibit

2.1 Amended and Restated Share Exchange Agreement, dated as of
July 13, 2016, by and among Biodel Inc., Albireo Limited and
the Sellers listed on Schedule I thereto. (incorporated by
reference to Exhibit2.1 to the Companys Current Report on
Form8-K filed with the Securities and Exchange Commission on
July 13, 2016).
3.1 Certificate of Amendment (Reverse Stock Split) to the
Restated Certificate of Incorporation of the Company, dated
November 3, 2016.
3.2 Certificate of Amendment (Name Change) to the Restated
Certificate of Incorporation of the Company, dated November
3, 2016.
4.1 Warrant to Purchase Common Stock of Albireo Pharma, Inc.,
dated November 4, 2016, issued to Kreos Capital IV (Expert
Fund) Limited.
10.1 Supplemental Deed, dated as of May 24, 2016, by and among
Kreos Capital IV (UK) Limited, Albireo Limited, Albireo AB
and Elobix AB, including as Schedule 1 thereto the Amended
and Restated Agreement for the Provision of a Loan Facility
of up to 6,000,000, dated as of December 18, 2014, by and
among Kreos Capital IV (UK) Limited, Albireo Limited, Albireo
AB and Elobix AB.
10.2 Guaranty and Security Agreement, dated as of November 4,
2016, by and between Albireo Pharma, Inc. and Kreos Capital
IV (UK) Limited.
10.3* Employment Agreement, dated as of July 27, 2015, by and
between Albireo, Inc. and Ronald H.W. Cooper.
10.4* Employment Agreement, dated as of February 14, 2008, by and
between Albireo AB and Jan P. Mattsson, Ph.D.

1

10.5* Employment Agreement, dated as of August4, 2016, by and
between Albireo, Inc. and Thomas A. Shea.
10.6* Employment Agreement, dated as of September 6, 2016, by and
between Albireo, Inc. and Paresh N. Soni, M.D., Ph.D.
10.7* Employment Agreement, dated as of February 17, 2016, by and
between Albireo, Inc. and Peter A. Zorn.
10.8* Formof Indemnification Agreement, by and between the Company
and each of its directors and executive officers.
10.9* Albireo Pharma,Inc. 2016 Equity Incentive Plan.
16.1 Letter from BDO USA, LLP dated November 3, 2016.
23.1 Consent of Ernst Young LLP, independent registered public
accounting firm, regarding the audited financial statements
of the Albireo Limited.
99.1 Press Release dated November 3, 2016.
99.2 Audited consolidated financial statements of Albireo Limited
as of and for the years ended December 31, 2015 and 2014 and
unaudited consolidated financial statements of Albireo
Limited as of June 30, 2016 and for the three and six months
ended June 30, 2016 and 2015.
99.3 Unaudited Pro Forma Condensed Combined Financial Statements
for the year ended December 31, 2015 and as of and for the
six months ended June 30, 2016.
99.4 Unaudited consolidated financial statements of Albireo
Limited as of September30, 2016 and for the three and nine
months ended September30, 2016 and 2015.

* Management contract or compensatory plan or arrangement.
Previously filed as an exhibit to the Original Form 8-K.

2


About ALBIREO PHARMA, INC. (NASDAQ:BIOD)

Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Its clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. Its pipeline includes A4250, A3384 and Elobixibat. The Company is developing A4250 as a treatment for pediatric orphan cholestatic liver diseases, such as progressive familial intrahepatic cholestasis (PFIC). The Company is developing A3384 for the treatment of bile acid malabsorption (BAM) disease. The Company is also developing Elobixibat as a treatment for chronic idiopathic constipation (CIC). A4250 and Elobixibat are selective inhibitors of the ileal bile acid transporter (IBAT). The Company has completed a Phase II clinical trial of a prototype of A3384 in over 19 subjects with BAM.

ALBIREO PHARMA, INC. (NASDAQ:BIOD) Recent Trading Information

ALBIREO PHARMA, INC. (NASDAQ:BIOD) closed its last trading session 00.00 at 19.46 with 2,338,156 shares trading hands.

An ad to help with our costs